TABLE OF CONTENTS      November/December 2015 • Volume 26 • Issue 6

 

Michel G Bergeron “MGB” – a true success
RF Omar, M Boissinot, C Giguere, S Trottier, D Beauchamp, B Lambert, CB Vincent


Digging for new solutions
L Valiquette, KB Laupland

Invasive disease due to Haemophilus influenzae type A in children in Canada’s north: A priority for prevention.
A-A Boisvert, D Moore

Letter to the Editor: Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients
CR O'Neil, JX Pang, SS Lee, MG Swain, KW Burak, P Klein, RP Myers, J Kapler, MJ Gill, M Labrie, CS Coffin

An unusual case of abdominal pain
S Vaughan, M Sadler, S Jayakumar, B Missaghi, W Chan, DL Church

Characterization of invasive Neisseria meningitidis from Atlantic Canada, 2009 to 2013: With special reference to the nonpolysaccharide vaccine targets (PorA, factor H binding protein, Neisseria heparin-binding antigen and Neisseria adhesin A)
RS Tsang, DK Law, RR Gad, T Mailman, G German, R Needle

Neisseria meningitidis can cause several invasive diseases. Serogroup distribution has been known to be related to geographical differences and, in Canada, most invasive meningococcal disease cases have been caused by serogroups B (MenB) and C. Following the introduction of a meningitis C vaccine, most cases are now caused by MenB. Characterization of invasive meningococcal disease case isolates from Atlantic Canada provides a snap shot of the molecular epidemiology, shedding light on the future of a MenB vaccine.


Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
GG Zhanel, AJ Walkty, JA Karlowsky

Oral vancomycin and oral metronidazole have several limitations with regard to their use in the treatment of Clostridium difficile infections (CDIs); however, oral vancomycin has been considered the gold standard in clinical trials. In June 2012, fidaxomicin received Health Canada approval for the treatment of CDIs. Its chemistry, mechanisms of action and pharmacological properties are discussed, along with its potential role in CDI therapy.


Edwardsiella tarda bacteremia. A rare but fatal water- and foodborne infection: Review of the literature and clinical cases from a single centre
Y Hirai, S Asahata-Tago, Y Ainoda, T Fujita, K Kikuchi

Risk factors of Edwardsiella tarda bacteremia are not well established. Analyzing previous reports and recent clinical cases to determine these risk factors, and examine the distribution and clinical epidemiology of Edwardsiella tarda bacteremia is important because although occurrence is rare, it can be fatal in humans.


Staphylococcus pettenkoferi bacteremia: A case report and review of the literature
AA Hashi, JA Delport, S Elsayed, MS Silverman

In 2002, the coagulase-negative staphylococci species Staphylococcus pettenkoferi was first described. In addition to an overview of the laboratory detection of uncommon coagulase-negative staphylococci, this report describes, to the author’s knowledge, the first case of S pettenkoferi bacteremia in Canada.


The role of empirical albendazole treatment in idiopathic hypereosinophilia – a case series
E Vaisben, R Brand, A Kadakh, F Nassar

Hypereosinophilia can lead to life-threatening organ damage when associated with eosinophilic infiltration of tissues. Although it is associated with a broad variety of diseases, sometimes no other abnormalities are detected. The authors present a novel approach to the treatment of hypereosinophilia, especially when an underlying cause fails to be detected.


Relapse of visceral leishmaniasis in an HIV-infected patient successfully treated with a combination of miltefosine and amphotericin B
S McQuarrie, K Kasper, DC Moffatt, D Marko, Y Keynan

Transmitted by the bite of female sandflies, leishmaniasis is a protozoal infection. Visceral leishmaniasis, which is usually transmitted by Leishmania donovani and Leishmania infantum, occurs when the reticuloendothelial system is affected, and is more severe in HIV-infected patients because it increases HIV viral replication, as described in this case report. The authors also describe gastrointestinal complications that occurred in both this case and in other visceral leishmaniasis cases from the literature.


Exogenous endophthalmitis caused by Enterococcus casseliflavus: A case report and discussion regarding treatment of intraocular infection with vancomycin-resistant enterococci
BM Berenger, S Kulkarni, BJ Hinz, SE Forgie

Due to poor penetration of systemic or topical antibiotics into the vitreous chamber, treating endophthalmitis is challenging, especially in rare cases in which vancomycin-resistant enterococci are present. Caused by the unique mechanism of high-velocity water stream trauma, a case of exogenous endophthalmitis in a four-year-old-boy is discussed.


Letter to the Editor: Are physicians obligated to tell parents about the meningococcal serogroup B vaccine?
JL Robinson

Corrigendum: Re: Dr MacFadden, WL Gold, I Al-Busaidi, et al. An educational forum to engage infectious diseases and microbiology residents in resource stewardship modelled after the Choosing Wisely campaign. Can J Infect Dis Med Microbiol 2015;26(5):231-233.
Pulsus Group Inc




Click here to unsubscribe.


Please take a moment to provide us with your feedback. It is only by working with readers, authors, society members and sponsors that this website will develop to meet the needs of everyone concerned.

Important Note: To ensure the receipt of the eTOC email please add CanadianJournalofInfectiousDiseasesAndMedicalMicrobiology@pulsus.com to your safe sender list.

Like us on Facebook
Follow us on Twitter

-